Alphatec (NASDAQ:ATEC) Shares Climb 5.1% – Here’s What Happened

Alphatec Holdings, Inc. (NASDAQ:ATEC) shot up 5.1% on Wednesday. The company traded as high as $11.35 and last traded at $11.4260. 431,688 shares changed hands during trading, a decline of 85% from the average daily volume of 2,871,678 shares. The stock had previously closed at $10.87.

Alphatec News Roundup

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: Third-quarter revenue rose 12.6% year over year to $221.17 million, while earnings increased to $0.09 per share from $0.03 a year earlier. However, both figures were below analyst expectations. Alphatec third-quarter earnings report
• Positive Sentiment: Management continues to target a 16% adjusted EBITDA margin for 2026, suggesting an emphasis on profitability and operating efficiency despite slower-than-expected revenue growth. Alphatec lowers fiscal 2026 revenue outlook
• Neutral Sentiment: The company’s quarterly results show continued commercial growth, but Alphatec remains unprofitable, with a negative net margin and analysts expecting a full-year loss. Alphatec third-quarter and nine-month results
• Negative Sentiment: Alphatec lowered its 2026 revenue forecast to $862 million, below the approximately $882 million FactSet estimate. The reduced outlook signals weaker near-term growth than investors had anticipated. Alphatec 2026 revenue outlook
• Negative Sentiment: BMO Capital Markets downgraded ATEC from “outperform” to “market perform” and set an $8.00 price target, implying roughly 29.6% downside from the referenced $11.37 price. BMO Capital Markets Alphatec rating

Analysts Set New Price Targets

ATEC has been the subject of several recent research reports. Wall Street Zen downgraded Alphatec from a “buy” rating to a “hold” rating in a report on Sunday, October 11th. Needham & Company LLC dropped their price objective on Alphatec from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday. TD Cowen reiterated a “buy” rating on shares of Alphatec in a research note on Friday. UBS Group boosted their target price on shares of Alphatec from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, Stephens began coverage on shares of Alphatec in a research note on Thursday, July 23rd. They set an “overweight” rating and a $15.00 price objective for the company. Twelve analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $17.00.

Alphatec Stock Performance

The stock has a market cap of $1.76 billion, a PE ratio of -16.01 and a beta of 0.78. The company has a 50 day moving average of $10.18 and a two-hundred day moving average of $10.67.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings results on Thursday, October 29th. The medical technology company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). Alphatec had a negative return on equity of 6,752.24% and a negative net margin of 13.49%. The company had revenue of $221.17 million during the quarter, compared to analysts’ expectations of $225.16 million. During the same period in the previous year, the firm posted $0.03 EPS. Alphatec’s revenue was up 12.6% compared to the same quarter last year. As a group, equities research analysts anticipate that Alphatec Holdings, Inc. will post -0.45 EPS for the current year.

Insider Transactions at Alphatec

In related news, CEO Patrick Miles bought 115,000 shares of the stock in a transaction dated Thursday, September 10th. The shares were acquired at an average cost of $8.81 per share, for a total transaction of $1,013,150.00. Following the acquisition, the chief executive officer directly owned 5,893,551 shares in the company, valued at approximately $51,922,184.31. This trade represents a 1.99% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Tyson Marshall sold 8,168 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $9.65, for a total transaction of $78,821.20. Following the transaction, the general counsel directly owned 630,398 shares in the company, valued at approximately $6,083,340.70. The trade was a 1.28% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 13.48% of the company’s stock.

Institutional Trading of Alphatec

A number of large investors have recently modified their holdings of the stock. Bank of America Corp DE lifted its position in shares of Alphatec by 26.9% during the 1st quarter. Bank of America Corp DE now owns 2,560,971 shares of the medical technology company’s stock worth $27,863,000 after purchasing an additional 543,059 shares during the last quarter. Emerald Advisers LLC grew its position in Alphatec by 10.4% during the 1st quarter. Emerald Advisers LLC now owns 1,807,307 shares of the medical technology company’s stock worth $19,664,000 after purchasing an additional 169,578 shares during the last quarter. Granite Investment Partners LLC grew its stake in shares of Alphatec by 4.7% in the 1st quarter. Granite Investment Partners LLC now owns 1,195,156 shares of the medical technology company’s stock valued at $13,003,000 after purchasing an additional 54,043 shares during the last quarter. Emerald Mutual Fund Advisers Trust increased its stake in Alphatec by 27.1% in the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 1,156,826 shares of the medical technology company’s stock valued at $12,586,000 after buying an additional 246,773 shares during the period. Finally, Paradigm Capital Management Inc. NY acquired a new stake in Alphatec in the second quarter valued at about $9,413,000. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Alphatec Company Profile

Alphatec Holdings, Inc is a medical technology company focused on the design, development and commercialization of products and procedural solutions for spine surgery. The company aims to improve the treatment of spinal disorders through technologies that support spinal fusion, deformity correction, reconstruction and minimally invasive procedures.

Its portfolio includes spinal implants, surgical instruments, navigation and imaging technologies, and intraoperative monitoring solutions.